Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...

Strategic in-licensing agreement with Hansoh Pharmaceuticals provides exclusive rights to develop and commercialize HS-20094, enhancing Regeneron's pipeline in obesity and metabolic programs.

Hansoh has already studied the drug in more than 1,000 patients, according to Regeneron, which claimed that HS-20094 has a “potentially similar profile” to Lilly’s approved GLP-1/GIP agonist.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094 ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China. The pharmaceutical company said ...

Triple combo therapy cut 30 pounds with just 2 lbs of lean mass lost, showing strong fat-targeting results in the midstage trial. Regeneron inks $80 million deal with Hansoh for Phase 3 obesity ...

Regeneron, listening to the call for more gene therapies, has added hearing loss specialist Decibel Therapeutics to its playlist in a deal valuing the biotech at $109 million at closing.